Abstract
To the Editor: Lymphomatoid papulosis is a cutaneous primary CD30+ lymphoproliferative disorder related to mycosis fungoides with a chronic course and an increased risk of lymphoma.1 None of the current available therapies is curative and this subjects the patient to multiple repeated and protracted treatment cycles with attendant acute and long-term toxicity.2 Because lymphomatoid papulosis responds to systemic interferon alfa-2a with a 5-month remission3 and because mycosis fungoides (a related lymphoproliferative disease) responds to topical imiquimod 5% cream (an inducer of local interferon production),4 it seems reasonable that lymphomatoid papulosis might respond to topical imiquimod cream.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
